P450 clinical measures of asthma control from the mometasone furoate/formoterol spiro trial

Asthma maintenance treatment aims to preserve asthma control in order to reduce the risk of asthma exacerbation. The combination between an inhaled corticosteroid and a fast-acting bronchodilator, systemic corticosteroids (SCS) bursts and other add-on asthma medications are prescribed for asthma worsening to mitigate serious outcomes.1 Primary findings from a 26-week double-blind, randomized-controlled trial in patients ≥12 years of age with persistent asthma comparing mometasone furoate/formoterol (MF/F) to MF did not demonstrate a significant difference in asthma-related hospitalizations, intubations and deaths, but did show a significant reduction in asthma exacerbation.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Pharmacology and Pharmacotherapeutics Source Type: research